skip to main content
Resource type Show Results with: Show Results with: Search type Index
Your initial search resulted in no hits. The results below were found by expanding your search.

62 Improvement of hearing with bevacizumab in a patient with neurofibromatosis type 2 and bilateral acoustic schwannomas

Yusuf, Dimas ; O’Kelly, Cian ; Easaw, Jacob C

Canadian journal of neurological sciences, 2018-06, Vol.45 (S3), p.S11-S11 [Peer Reviewed Journal]

No full-text

Citations Cited by
  • Title:
    62 Improvement of hearing with bevacizumab in a patient with neurofibromatosis type 2 and bilateral acoustic schwannomas
  • Author: Yusuf, Dimas ; O’Kelly, Cian ; Easaw, Jacob C
  • Subjects: 10 MAY 2018 @ 1800-1900: 11 MAY 2018 @ 1620-1720: 12 MAY 2018 @ 1010-1035 ; POSTER VIEWING SESSIONS
  • Is Part Of: Canadian journal of neurological sciences, 2018-06, Vol.45 (S3), p.S11-S11
  • Description: BACKGROUND: Neurofibromatosis type 2 (NF2) is a rare genetic condition caused by mutations in the Merlin gene on chromosome 22. It results in acoustic neuromas (schwannomas) and other CNS tumors including meningiomas and ependymomas. Most patients develop hearing loss as a result of neuroma-driven destruction of auditory nerves. Surgery and radiation therapy remain the two most commonly recommended treatment options. However, there is a risk of further hearing loss with these procedures. There is emerging evidence that bevacizumab, a monoclonal antibody against VEGF-A, can shrink acoustic neuromas and mitigate hearing loss. CASE PRESENTATION: A 34-year-old female with bilateral acoustic neuromas from NF2 suffers partial hearing loss in the left ear and total hearing loss in the right ear after removal of the right-sided neuroma. Baseline MRI showed a left-sided acoustic neuroma (15 x 13 mm) and recurrence of the right-sided neuroma (18 x 14 mm). Bevacizumab was initiated at 5 mg/kg IV every 14 days. After 8 cycles, the patient reported marked improvement in hearing. At lower frequencies (< 1,000 Hz, the range of human voice), auditory thresholds improved by up to 60% of baseline, while at higher frequencies, improvements of up to 46% were seen. Repeat imaging showed no disease progression. CONCLUSIONS: Bevacizumab led to hearing improvement and prevention of disease progression after 8 cycles of therapy. This treatment should be considered in patients with NF2 and acoustic neuromas who wish to pursue a less-invasive treatment option with the potential of delaying progression and mitigating hearing loss.
  • Publisher: New York, USA: Cambridge University Press
  • Language: English
  • Identifier: ISSN: 0317-1671
    EISSN: 2057-0155
    DOI: 10.1017/cjn.2018.310

Searching Remote Databases, Please Wait

  • Searching for
  • inscope:(TRAILS-PRINT),scope:(D-01TRAILS_MSU_GFC),scope:(E-01TRAILS_MSU_GFC),primo_central_multiple_fe
  • Show me what you have so far